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Gluconeogenesis makes a major contribution to
hepatic glucose production, a process critical for
survival in mammals. In this study, we identify the
p160 family member, SRC-1, as a key coordinator of
the hepatic gluconeogenic program in vivo. SRC-
1-null mice displayed hypoglycemia secondary to
a deficit in hepatic glucose production. Selective re-
expression of SRC-1 in the liver restored blood
glucose levels to a normal range. SRC-1 was found
induced upon fasting to coordinate in a cell-autono-
mous manner, the gene expression of rate-limiting
enzymes of the gluconeogenic pathway. At the
molecular level, the main role of SRC-1 was tomodu-
late the expression and the activity of C/EBPa
through a feed-forward loop in which SRC-1 used
C/EBPa to transactivate pyruvate carboxylase,
a crucial gene for initiation of the gluconeogenic
program. We propose that SRC-1 acts as a critical
mediator of glucose homeostasis in the liver by ad-
justing the transcriptional activity of key genes
involved in the hepatic glucose production
machinery.
INTRODUCTION
Throughout evolution, organisms have devised metabolic strat-
egies to survive during long periods of starvation. Some organ-
isms are able to place their own metabolism on ‘‘pause’’
(hypometabolism or even ametabolism) to sustain them during
extreme environmental conditions (Storey and Storey, 2007).
Humans and most other higher mammals have abandoned this
type of extreme adaptation by developing alternative regulatory
circuits that allow for maintenance of cellular energy (ATP) in vital
tissues. While metabolic adaptation during fasting involves
a variety of tissues, the liver plays the key role in the orchestration
of this complex phenomenon (Cahill, 2006). During fasting,606 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 Elsevierhepatic glucose production is required to maintain blood sugar
levels in a normal range, ensuring a sufficient supply of energy
for the central nervous system (Roden et al., 2001). Shortly after
food withdrawal, liver glycogen stores are depleted and gluco-
neogenesis becomes the main contributor to hepatic glucose
production and survival (Newgard, 2004). The rate of gluconeo-
genic flux is controlled by the activities of key enzymes such as
pyruvate carboxylase (PC), phosphoenolpyruvate carboxy-
kinase (PEPCK), fructose-1, 6-bisphosphatase (FBP1), and
glucose-6-phosphatase (G6Pase) (Granner and Pilkis, 1990).
As a result of the epidemic expansion of type 2 diabetes (Doria
et al., 2008), and because dysregulation of gluconeogenesis is
one of the major contributing factors of this metabolic disorder,
there is currently a need for a better understanding of mecha-
nisms and the transcriptional players that drive the gluconeo-
genic program in vivo. Recent studies using knockout animals
of transcriptional factors and coregulators including PGC-1a,
CRTC2, and SIRT1 strongly suggest that additional factors are
likely to be involved in the control of hepatic glucose production
(Chen et al., 2008; Le Lay et al., 2009; Leone et al., 2005; Lin
et al., 2004).
The p160 family of coactivators includes SRC-1 (NCOA1),
SRC-2 (TIF2, GRIP1, NCOA2), and SRC-3 (AIB1, ACTR,
TRAM1, RAC3, p/CIP, NCOA3). These coregulators have been
studied extensively for their transcriptional control mechanisms
in cell culture, but their physiological roles in vivo are less under-
stood. Nevertheless, previous studies have revealed regulatory
roles for this family in certain aspects of metabolism (Louet
et al., 2006; Louet and O’Malley, 2007; Picard et al., 2002).
SRC-3 has been implicated in adaptive thermogenesis regula-
tion via modulation of PGC-1a activity in skeletal muscle and
brown adipose tissue (Coste et al., 2008). In the liver, SRC-2
interacts with RORa to control the expression of the G6Pase
gene, and its ablation results in a glycogen storage-1a-like
(Von Gierke’s) syndrome (Chopra et al., 2008). The specific
metabolic roles of SRC-1 remain unknown.
In the present study, we found that the hepatic expression of
SRC-1 gene was increased during the fed-to-fasting metabolic
switch. A critical role for SRC-1 in the control of hepatic glucose
production was uncovered by study of SRC-1-null mice that
were hypoglycemic in fed and in fasting states despite anInc.
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Figure 1. Impact of SRC-1 on Fasting Glycemia Is Liver Dependent
(A) SRC-1 and SRC-3 gene expression are increased in the liver during fed-to-fasting transition. The gene expression of the p160 family of coactivators and
PGC-1a was measured by qPCR in the liver of WT animals in the fed state (n = 5 mice per group) and upon 24 hr of fasting (n = 5 mice per group).
(B) Ablation of SRC-1 results in fed and fasting hypoglycemia. Blood glucose levels were determined in SRC-1 knockout (KO) and WT mice during ad libitum
feeding (n = 5 mice per group) and after 24 hr of fasting (n = 12–15 mice per group) with a hand-held glucometer.
(C and D) SRC-1 KO mice exhibit normal insulin sensitivity. Glucose tolerance test and insulin tolerance test were performed after 4 hr of fasting (n = 6 mice per
group).
(E and F) Correction of hypoglycemia in SRC-1 KOmice by adenovirus-mediated re-expression of SRC-1.SRC-1 expression levels measured by qPCR in the liver
(n = 4mice per group) of theWT and the KO groups treated with a control (empty) adenovirus (WT+GFP or KO+GFP) and the KO group treated with an adenovirus
expressing SRC-1 (KO+SRC-1) (E). Blood glucose levels were determined inmice (n = 4mice per group) fasted 16 hr on two consecutive days (Day+3, left; Day+4,
right) after adenovirus treatment (F). Data are shown for the WT and KO groups treated with control adenovirus (WT+GFP or KO+GFP) and for the KO group
treated with an adenovirus expressing SRC-1 (KO+SRC-1).
Data are represented as mean + SEM. Unpaired student’s t test was used for evaluation of statistical significance. One asterisk indicates p < 0.05, two asterisks
indicate p < 0.01, and three asterisks indicate p < 0.005. See also Figure S1.
Cell Metabolism
Role of SRC-1 in Hepatic Gluconeogenesisabsence of increased insulin secretion or peripheral insulin
sensitivity. Screening for alterations of the gene expression of
key metabolic enzymes revealed impairment in the gluconeo-
genic program in SRC-1-null mice. Dissection of the underlying
molecular mechanisms identified SRC-1 as a critical mediator
of glucose homeostasis in the liver in the fed-to-fasting
transition.
RESULTS
SRC-1 Knockout Mice Are Hypoglycemic because
of a Liver Metabolic Defect
In an attempt to uncover new metabolic functions for the p160
family of coactivators, we monitored SRC family gene expres-
sion in the liver by qPCR during the transition between theCell Mfed-to-fasting states and found that the hepatic expression of
SRC-1 andSRC-3were significantly increased upon fasting (Fig-
ure 1A). As previously described, PGC-1a messenger RNA
(mRNA) was increased (Yoon et al., 2001), whereas SRC-2
expression was not changed (Figure 1A). Since one of the major
functions of the liver during the fed-to-fasting transition is to
maintain blood sugar in a normal range, we further characterized
the importance of SRC-1 and SRC-3 by determining the blood
glucose levels in animals with global KOs of these two coactiva-
tors. We observed a significant decrease in blood glucose levels
in fasted (and also in randomly fed) SRC-1-null animals
compared to wild-type (WT) animals (Figure 1B); no significant
differences were found in the SRC-3 knockout (KO) mice (Fig-
ure S1A available online). On the basis of this observation, we
performed detailed phenotypic analyses of the SRC-1-null mice.etabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc. 607
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Figure 2. Hepatic Glucose Production Is
Impaired in SRC-1 KO Mice
(A) In vivo glucose production is decreased in
SRC-1 KO mice. Glucose production was per-
formed on SRC-1-null and WT mice after an
overnight fast (16 hr) in order to assess basal
hepatic glucose production (n = 5 mice per group).
(B and C) SRC-1 affects glucose production in
primary hepatocytes. Measurement of glucose
production in primary hepatocytes from WT or
SRC-1-null animals after induction of gluconeo-
genesis with dexametasone and forskolin is shown
in (B). Measurement of basal glucose production
48 hr after overexpression of SRC-1 or, as
a control, GFP is shown in (C).
Data are represented as mean + SEM. Unpaired
student’s t test was used for evaluation of statis-
tical significance. One asterisk indicates
p < 0.05, two asterisks indicate p < 0.01, and three
asterisks indicate p < 0.005.
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Role of SRC-1 in Hepatic GluconeogenesisDecreased blood glucose levels in SRC-1-null mice were not
a consequence of increased secretion of pancreatic insulin in
fasting conditions (Figure S1B). Levels of glucagon, corticoste-
roids, and IGF-1, as well as circulating free fatty acids or triglyc-
erides, were unchanged in plasma upon fasting (Figures S1B and
S1C). Global in vivo lipolysis was unimpaired in SRC-1 KO mice,
as evidenced by equal increases in fatty acids and glycerol in
blood of SRC-1 KO mice and WT mice after 4 hr of fasting, or
after fasting and injection of CL316243, a beta-3 adrenergic
receptor agonist; these results indicate no fundamental defects
in regulation of lipolysis in white adipose tissue (Figure S1D).
Insulin sensitivity of SRC-1 KO mice was similar to that of WT
animals, based on glucose and insulin tolerance tests (Figures
1C and 1D). Finally, no differences were found in physical
activity, body weight, food consumption, percentage of fat
mass, and energy expenditure between the KO and WT animals
(Figures S1E and S1F). Therefore, the hypoglycemia observed in
SRC-1-null mice suggested a hepatic defect.
SRC-1 Depletion Impairs Hepatic Glucose Production
To demonstrate that the liver was the primary cause of the hypo-
glycemia in SRC-1-null animals, we re-expressed the SRC-1 co-
activator selectively in the liver through the injections of an
adenovirus encoding SRC-1. This approach restored hepatic
expression ofSRC-1 to levels similar to those ofWT animals (Fig-
ure 1E) and resulted in complete normalization of blood glucose
levels after 16 hr of fasting (Figure 1F). To substantiate this
finding, we determined in vivo glucose production and found608 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc.a clear defect in hepatic glucose produc-
tion in the SRC-1 KO mice upon fasting
(Figure 2A). In primary hepatocytes from
SRC-1 KO mice, hormonal induction of
glucose production by glucocorticoids
and cAMP was significantly decreased
compared to WT cells (Figure 2B).
Conversely, adenovirus-mediated over-
expression of SRC-1 in primary hepato-
cytes increased glucose output (Fig-ure 2C). Thus, SRC-1 appears to function as an important
regulator of hepatic glucose production in response to fasting.
SRC-1 Controls the Gene Expression of Key
Gluconeogenic Enzymes In Vivo
In order to understand themolecular mechanisms underlying the
impact of SRC-1 on the control of hepatic glucose production,
we next focused on glycogenolysis and gluconeogenesis, two
major pathways involved in glucose production by the liver. No
significant difference was found between the hepatic glycogen
content of knockout versus wild-type animals regardless of the
nutritional status (Figure 3A). We also found that key glycogenol-
ysis geneswere not impaired upon fasting (Figure S2A), suggest-
ing that glycogenolysis was not affected by the absence of
SRC-1. We therefore shifted our attention to key genes that
control critical steps of gluconeogenesis. Interestingly, PEPCK
mRNA levels were found to be significantly decreased in fed
status in SRC-1 KOmice compared toWTmice without reaching
significance upon fasting, whereas G6Pase gene expression
was globally not significantly impaired (Figure 3B). A significant
decrease was also noted for FBP1 gene expression in fed and
in fasting, suggesting a control of this major gluconeogenic
enzyme by SRC1 (Figure 3B). Additionally, mRNA levels of PC
were decreased in SRC-1 KO mice compared to WT littermates
upon fasting (Figure 3B). This is of importance since one of the
critical checkpoints for the adequate metabolic adaptation of
the liver to fasting is the increase of the activity of PC, which
allows the liver to switch from an organ oxidizing glucose and
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Figure 3. SRC-1 Controls the Hepatic Gluconeogenic Program
(A) SRC-1 does not influence the glycogenolysis pathway in the liver. Liver glycogen content was measured in liver of WT and SRC-1 KO animals under fed
(n = 5 mice per group) or 24 hr fasted (n = 5 mice per group) conditions.
(B) SRC-1 regulation of key genes in the gluconeogenic pathway in liver during the fasting adaptation. mRNA levels for the indicated genes were measured by
qPCR in the liver of WT animals under fed (n = 5 mice per group) and fasted (n = 5 mice per group) conditions. PEPCK, phosphoenolpyruvate carboxykinase,
cytosolic isoform; G6Pase, glucose-6-phosphatase; FBP1, fructose-1,6-bisphosphatase; PC, pyruvate carboxylase.
(C) Hypercitrullinemia in SRC-1 KO mice. Citrulline levels in plasma of fasted (24 hr) WT and SRC-1 KO mice (n = 5 mice per group).
(D) Impact of SRC-1 on important genes of the b-oxidation pathway in the liver. mRNA levels for the indicated genes were measured qPCR in the liver of WT and
SRC-1 KO animals in fed (n = 5 mice per group) and 24 hr fasted mice (n = 5 mice per group). L-CPT1, carnitine palmitoyltransferase 1a, liver;MCAD, acyl-coen-
zyme A dehydrogenase, medium chain; LCAD, acyl-coenzyme A dehydrogenase, long chain; VLCAD, acyl-coenzyme A dehydrogenase, very long chain; AOX,
acyl-coenzyme A oxidase 1.
(E) mRNA levels for several important genes involved in glycolysis and lipogenesis pathways. FAS, ACC1, SCD1 (lipogenesis) and L-PK, ChREBP, Glut2, and
PFK1 (glycolysis) mRNA levels were measured by qPCR in the liver of SRC-1 KO and WT animals after 24 hr of fasting (n = 5 mice per group). FAS, fatty acid
synthase; ACC1, acetyl-CoA carboxylase; SCD1, stearoyl-CoA desatuase 1; L-PK, pyruvate kinase, liver isoform; ChREBP, carbohydrate responsive element
binding protein; Glut2, glucose transporter 2; PFK1, phosphofructose kinase 1.
Data are represented as mean + SEM. Unpaired student’s t test was used for evaluation of statistical significance. One asterisk indicates p < 0.05, two asterisks
indicate p < 0.01, and three asterisks indicate p < 0.005. See also Figure S2.
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Role of SRC-1 in Hepatic Gluconeogenesisesterifying fatty acids into triglycerides during the fed condition
to an organ mainly producing glucose and oxidizing fat upon
fasting (Desvergne et al., 2006). Of note, accumulation of citrul-
line was found in the liver and the plasma of SRC-1 KO animals
compared to the WT (Figure S2B and Figure 3C), similarly to that
found in human patients presenting with PC deficiency (Garcı´a-
Cazorla et al., 2006). Re-expression of SRC-1 in the liver of SRC1
KO mice restored plasma citrulline levels to a normal range (Fig-
ure S2C), thus reinforcing the finding that SRC-1 is a major regu-
lator of PC in vivo.
Since impairment in the hepatic b-oxidation pathway was
found associated with hypoglycemia in humans (Eaton, 2002;
Foster, 2004), the impact of SRC-1 on this pathway was investi-Cell Mgated by testing the gene expression profile of key genes of this
pathway. Only minor differences in mRNA levels of fatty oxida-
tion genes compared to WT were detected (Figure 3D), suggest-
ing that SRC-1 was not a key regulator of b-oxidation in the liver.
Finally, we also assessed the expression levels of hepatic
genes involved in glycolysis and lipogenesis, two pathways
that are normally decreased during fasting, in order to spare
glucose. An abnormally high activity of these pathways can
indeed result in hypoglycemia under food restriction (Magnuson
et al., 2003). In SRC-1-null mice, none of the tested glycolytic or
lipogenic genes showed an increase of their gene expression
(Figure 3E). Instead, two glycolytic genes, the glucose trans-
porter 2 (Glut2) and phosphofructokinase1 (PFK1), were foundetabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc. 609
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Figure 4. SRC-1 Controls Gluconeogenic Genes in a Cell-Autonomous Manner
(A) mRNA levels for several important gluconeogenic genes are decreased in primary hepatocytes from SRC-1 KO mice. AS, argininosuccinate synthetase
(B) SRC-1 controls gluconeogenic genes that are not responsive to PGC-1a. Primary hepatocytes were treated with SRC-1 or PGC-1a adenoviruses and studied
48 hr after viral treatment. The gene expression level of specific target genes was evaluated by qPCR.
(C and D) Specific knockdown of PGC-1a does not influence the activation of PEPCK by SRC-1. The mRNA levels of PGC-1a were decreased via siRNA in
Hepa1.6 cells and then overexpressed by SRC-1 with adenoviruses during 48 hr. The gene expression level of PEPCK was evaluated by qPCR.
(E) SRC-1mRNA levels (measured by qPCR) are increased inWT hepatocytes by 24 hr of exposure to dexamethasone or forskolin or dexamethasone + forskolin.
(F) SRC-1 protein levels increase in hepatocytes treated with dexamethasone + forskolin. SRC-1 protein levels were measured by immunoblot (western) analysis
in hepatocytes from SRC-1 KO and WT littermates after 24 hr of treatment with dexamethasone and forskolin. D, dexamethasone; F, forskolin.
Data are represented asmean + SEM of three independent experiments. Unpaired student’s t test was used for evaluation of statistical significance. One asterisk
indicates p < 0.05, two asterisks indicate p < 0.01, and three asterisks indicate p < 0.005. See also Figure S3.
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Role of SRC-1 in Hepatic Gluconeogenesisto be decreased in fasted SRC-1 KOmice compared toWTmice
(Figure 3E).
Together, numerous important metabolic genes were quanti-
fied by qPCR for their in vivo expression in SRC-1-depleted livers
during the transition from fed to fasting states. From this anal-
ysis, we concluded that SRC-1 is a crucial coordinator of the
expression of specific key gluconeogenic regulators in the liver,
but that it does not exert appreciable control of expression of
genes dedicated to glycogenolysis, b-oxidation, glycolysis,
and lipogenesis.
Cell-Autonomous Action of SRC-1 on the Control
of Critical Gluconeogenic Genes
To test for a cell-autonomous effect of SRC-1 on the gluconeo-
genic program, we compared the mRNA levels of key gluconeo-
genic genes in primary hepatocytes isolated from SRC-1 KO610 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 Elseviermice and their WT littermates. As expected, we found that abla-
tion of SRC-1 significantly affected the transcription of FBP1 and
PC (Figure 4A), confirming our in vivo results. No defect was
found on the argininosuccinate synthetase (AS) gene expres-
sion, an important hepatic gene involved in the urea cycle (Fig-
ure 4A). Interestingly, whereas the impact of the abrogation of
SRC-1 on PEPCK in intact animals was observed only in
a randomly fed status and not in response to a long-term fasting,
isolated hepatocytes from SRC-1 knockout mice did show
a lower expression of the endogenous PEPCK compared to
WT (Figure 4A). This observation suggested that (1) PEPCK
could be a potential target gene of SRC-1 and the role of which
would be to maintain the basal activity of this enzyme in between
meals and (2) that in vivo complex intertissular and hormonal
interactions occurring upon fasting might ‘‘mask’’ this transcrip-
tional regulation.Inc.
Cell Metabolism
Role of SRC-1 in Hepatic GluconeogenesisWe next compared the action of SRC-1 and PGC-1a, another
important metabolic coactivator known to control gluconeogen-
esis. By using an adenoviral strategy in primary hepatocytes, we
found that SRC-1 controlled PC and FBP1 while overexpressed
PGC-1a did not upregulated them (Figure 4B).PEPCKwas found
regulated by both SRC-1 and PGC-1a (Figure 4B).
To investigate the possibility that SRC-1 might regulate tran-
scription via molecular mechanisms distinct from those used
by PGC-1a, we first checked the impact of SRC-1 on the PEPCK
gene expression in hepatocytes where PGC-1a gene expression
was specifically decreased by small interfering RNA (siRNA). We
found that a strong decreased of PGC-1a mRNA (Figure 4C)
levels had no effect on the SRC-1-dependent activation of
PEPCK (Figure 4D). This result strongly suggesta that SRC-1
and PGC-1a control PEPCK via independent mechanisms.
Finally, we reproduced the fasting induction of the expres-
sion of endogenous SRC-1 gene in the context of isolated
hepatocytes by using glucocorticoids and cAMP (Figure 4E),
whereas insulin was without significant effect (Figure S3A).
These observations confirmed that SRC-1 is regulated at the
level of transcription by hormonal and cellular signals specific
to the fasting liver. Induction of the SRC-1 protein also
occurred in a cellular context as well as in vivo (Figure 4F
and Figure S3B).
SRC-1 Controls the Gene Expression
and the Transcriptional Activity of C/EBPa upon Fasting
To determine the molecular mechanisms underlying the impact
of SRC-1 on gluconeogenesis, we next investigated hepatic
mRNA levels of several important transcription factors known
to be involved in the fasting metabolic transition (Desvergne
et al., 2006). Out of ten tested transcriptional factors, only
C/EBPa and FOXO1 were found to be significantly decreased
in fasted SRC-1-null animals compared to WT mice (Figure 5A).
These transcription factors are key players in the control of
glucose production by the liver in vivo, as their respective KO
mice present with profound hypoglycemia (Darlington et al.,
1995; Matsumoto et al., 2007). While FOXO1 is known to act
via PGC-1a to control hepatic glucose production (Puigserver
et al., 2003), the molecular players with C/EBPa are still
unknown. In our hands, when C/EBPa mRNA levels were
assessed in primary hepatocytes in which SRC-1 was overex-
pressed, we found that the SRC-1 coactivator induced endoge-
nous C/EBPa gene expression (Figure 5B). Moreover, this effect
was selective to SRC-1 as overexpressing PGC-1a had no effect
on C/EBPa mRNA levels (Figure 5B). We then checked the
expression level of C/EBPa in the isolated SRC-1 KO hepato-
cytes and found a significant decrease in KO cells compared
to the WT (Figure 5C). Then, specific binding of SRC-1 on the
C/EBPa promoter was investigated in mouse liver with chro-
matin immunoprecipitation (ChIP) assays in different key
metabolic conditions, which are refed, postabsorptive (fed),
and fasting (24 hr) animals. Interestingly, SRC-1 was not found
in the C/EBPa promoter when animals were refed (Figure 5D).
In contrast, a strong binding of SRC-1 was demonstrated on
this promoter in postabsorptive status and declined after 24 hr
of fasting (Figure 5D). We also confirmed the constitutive pres-
ence of C/EBPa on its own promoter (Figure 5D), as demon-
strated by others (Timchenko et al., 1995).Cell MWe next investigated the potential physical interaction
between C/EBPa and SRC-1 by coimmunoprecipitation and
found them in the same protein complexes in a cellular context
and in the liver (Figure 5E and Figure S4A). Furthermore, we
demonstrated a functional effect of SRC-1 on the promoter of
C/EBPa by using C/EBPa itself as the transcription factor, as
we observed a strong synergistic effect when these two proteins
were coexpressed (Figure 5F). The effect of SRC-1 on the
C/EBPa promoter was dependent upon the C/EBP response
element (C/EBP-RE), since (1) the specific mutation of C/EBP-
RE in the context of the C/EBPa natural promoter significantly
reduced the synergistic effect observed when SRC-1 and
C/EBPa were coexpressed (Figure 5F) and (2) an artificial
promoter containing only multicopies of this C/EBP-RE motif
was also strongly activated after coexpression of SRC-1 and
C/EBPa (Figure S4B). The functional cooperation between
C/EBPa and SRC-1was not due to the histone acetylase domain
of SRC-1 (HAT) but was in part due to one of its activation
domains (AD2) (Figure S4C). Taken together, our data provide
strong evidence supporting a direct control of SRC-1 on both
the gene expression and the transcriptional activity of C/EBPa.
A Central Role for the C/EBPa-PC Axis in the Control
of Hepatic Glucose Production by SRC-1
To identify the molecular targets of C/EBPa in the hepatic gluco-
neogenic program, we used recombinant adenoviruses to over-
express it in primary hepatocytes. We first observed that
increasing the mRNA levels of C/EBPa (Figure S5A) affected
the gene expression of FOXO1 (Figure 6A), confirming a tight
functional cooperation between these two transcription factors
in the liver as suggested in a previous study (Sekine et al.,
2007). This result could explain why the FOXO1 mRNA levels
dropped in SRC-1 KO consequent to a reduction of C/EBPa
gene expression (Figure 5A). No effect was observed on the clas-
sical key enzymes of the gluconeogenic program such as
PEPCK and G6Pase, which seems surprising considering
in vitro promoter studies previously performed on these genes,
especially PEPCK (Park et al., 1993; Park et al., 1990; Roesler
et al., 1998). However, this result mirrored the absence of altered
PEPCK and G6Pase expression observed in liver-specific
C/EBPa KO mice (Inoue et al., 2004). Interestingly, we found
a robust increase on the gene expression levels ofPC (Figure 6A).
On the basis of this result, we decided to study in more depth the
transcriptional effect of C/EBPa on the PC gene. By using an
in silico approach, we identified a potential C/EBP response
element in close proximity to the start site of the PC promoter.
Chromatin immunoprecipitation analysis revealed direct binding
of both C/EBPa and SRC-1 to this region of the PC promoter,
and this specifically in fasting condition, as no recruitment of
these two proteins was found in the liver of refed animals (Fig-
ure 6B). Moreover, a transactivation assay with the PC promoter
revealed extensive synergism between C/EBPa and SRC-1
(Figure 6C).
To further investigate SRC-1 as a key regulator of the C/EBPa
and the PC genes in vivo, we put KO and WT mice on a high-
protein diet, a diet known to activate the gluconeogenic pathway
in vivo (Jungas et al., 1992). After 3 weeks on this diet, SRC-1 KO
mice were found to be clearly hypoglycemic compared to WT
animals (Figure 6D). In this context, PCmRNA and protein levelsetabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc. 611
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Figure 5. The Coactivator SRC-1 Controls the Expression and the Transcriptional Activity of the C/EBPa Gene
(A) C/EBPa and FOXO1 mRNA levels are decreased in the liver of SRC-1 KO mice upon fasting. Gene expression levels of several transcription factors were
determined by qPCR in the liver (n = 5 mice per group). HNF4a, hepatic nuclear factor 4 alpha; CREB, cAMP response element (CRE)-binding protein;
C/EBPa, CAAT-enhancer binding protein alpha; C/EBPb, CAAT-enhancer binding protein beta; ERa, estrogen receptor alpha; STAT5beta, signal transducer
and activator of transcription 5 beta; RXRa, retinoid X receptor alpha; FOXO1, forkhead box O1; PPARa, peroxysome proliferator activated receptor alpha;
PPARd, peroxysome proliferator activated receptor delta.
(B) Overexpression of SRC-1 activates C/EBPa gene expression in primary hepatocytes. Mouse hepatocytes were treated with SRC-1 or PGC-1a adenoviruses
and harvested 48 hr later for measurement of C/EBPa mRNA by qPCR.
(C) mRNA levels for C/EBPa are decreased in primary hepatocytes from SRC-1 KO mice.
(D) In the mouse liver, SRC-1 binds theC/EBPa promoter in the region containing C/EBPa-responsive elements in fasting condition. ChIP assays were performed
in refed, postabsorptive, and fasting (24 hr) conditions with 221 bp amplicons flanking the region containing the C/EBPamotifs. qPCR (normalized to input) was
used to assess SRC-1 and C/EBPa occupancy of the C/EBPa promoter upon chromatin immunoprecipitation, with SRC-1- and C/EBPa-specific antibodies.
(E) SRC-1 and C/EBPa are found in the same complexes. Coimmunoprecipitation was performed after overexpression of SRC-1/flag and C/EBPa in the 293/T
cell line.
(F) SRC-1 controls theC/EBPa promoter through the use of C/EBPa as its transcriptional factor partner. HeLa cells were transfected with the C/EBPa promoter in
the native context (WT) or mutated for major C/EBP-RE elements (mut) in the presence of SRC-1, C/EBPa, or both expression vectors. Luciferase activity was
measured after an additional 48 hr of cell culture and is presented as fold increase compared to empty vector.
Data are represented as mean + SEM of two independent experiments performed in triplicate. Unpaired student’s t test was used for evaluation of statistical
significance. One asterisk indicates p < 0.05, two asterisks indicate p < 0.01, and three asterisks indicate p < 0.005. See also Figure S4.
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well as theC/EBPa, PEPCK, and FOXO1mRNA levels (Figure 6E
and Figure S5B).
To validate the importance of C/EBPa in the control of the
glucose production by SRC-1, we decided to acutely re-ex-
pressed C/EBPa in the context of primary hepatocytes and
also specifically in the liver of SRC-1 KO mice using adenovirus
approach. Importantly, we observed that the re-expression of
C/EBPa alone was able to partially rescue the impaired glucose612 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 Elsevierproduction in primary hepatocytes (Figure 6F) and in the liver
(Figure 6G), therefore validating our model placing C/EBPa-PC
axis in the center of the control of glucose production by
SRC-1. It is noteworthy, however, that re-expression of
C/EBPa in vitro and in vivo did not restore glucose production
to the level observed in WT cells, most likely because (1)
SRC-1 is necessary to the maximal action of C/EBPa, as we
showed previously in this study, and (2) the FBP1 gene, another
key target of SRC-1 in the liver, is not under the control ofInc.
AF G H I
B
C D E
Figure 6. Glucose Production Impairment in SRC-1 KO Hepatocytes Is Rescued by C/EBPa Re-expression
(A) C/EBPa controls PC and FOXO1 gene expression but not other important known genes of the gluconeogenic pathway. Primary hepatocytes were treatedwith
a C/EBPa adenovirus or empty virus (GFP) and used 48 hr later for measurement of gluconeogenic gene mRNA by qPCR.
(B) In the mouse liver, C/EBPa and SRC-1 bind to the PC promoter in the region containing C/EBPa-responsive elements specifically upon fasting. ChIP assays
were performed with 100 bp amplicons flanking the region containing the C/EBPa motifs of the PC promoter. qPCR (normalized to input) was used to assess
SRC-1 and C/EBPa occupancy of the PC promoter upon chromatin immunoprecipitation, with SRC-1- and C/EBPa-specific antibodies.
(C) The combination of C/EBPa and SRC-1 controls the PC promoter in a synergistic manner. HeLa cells were transfected in the presence of the proximal
promoter of the PC gene in presence of C/EBPa, SRC-1, or both expression vectors.
(D) SRC-1 KO mice placed on a high-protein diet are hypoglycemic. Blood glucose levels were determined in mice in the fed state (n = 5 mice) with a hand-held
glucometer.
(E) In SRC-1 KO mice placed on a high-protein diet, PC and C/EBPa gene expression are decreased. PC and C/EBPamRNA levels were measured by qPCR in
the liver of KO and WT animals in the fed state (n = 5 mice per group).
(F) Acute overexpression of C/EBPa reactivates glucose production in primary hepatocytes from SRC-1 KOmice. Primary hepatocytes from SRC-1 KOmice and
WT littermates were treated with C/EBPa or GFP adenoviruses and cultured for an additional 48 hr prior to measurement of glucose production over a period of
6 hr in the presence of forskolin and dexamethasone.
(G) Re-expression of C/EBPa in liver rescued the glucose production in SRC-1 KO mice. Adenoviruses (GFP and C/EBPa) were injected via the tail vein of each
mouse (n = 5–6 for each group). Blood glucose was checked after 7 days of infection using a hand-held glucometer.
(H) SRC-1 LiKO mice are hypoglycemic upon fasting. Blood glucose levels were determined in mice (n = 5 mice) in the fasted state (24 hr) with a hand-held gluc-
ometer.
(I) In SRC-1 liKOmice placed on fasting conditions,PC andC/EBPa gene expression are decreased.PC andC/EBPamRNA levels weremeasured by qPCR in the
liver of KO and WT animals (n = 3–4 mice per group) upon fasting (24 hr).
Data are represented as mean + SEM. Unpaired student’s t test was used for evaluation of statistical significance. One asterisk indicates p < 0.05, two asterisks
indicate p < 0.01, and three asterisks indicate p < 0.005. See also Figure S5.
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Figure 7. Kinetics of Induction of SRC-1,
C/EBPa, and PC during the Fed-to-Fasting
Transition in Liver
(A) SRC-1, C/EBPa, and PC mRNA levels are
increasing during early and late fasting in vivo.
The gene expression of SRC-1, C/EBPa, and PC
was measured by qPCR in the liver of WT animals
in the refed state (n = 5 mice per group), and upon
4 hr (n = 5 mice per group) and 24 hr of fasting
(n = 5 mice per group). Data are represented as
mean + SEM. Unpaired student’s t test was used
for evaluation of statistical significance. One
asterisk indicates p < 0.05, two asterisks indicate
p < 0.01, and three asterisks indicate p < 0.005.
(B) Schematic representation of the SRC-1 role on
the gluconeogenic pathway in vivo. SRC-1
controls the gene expression of key enzymes
involved in gluconeogenesis such as PEPCK,
FBP1, and PC. During a short-term fasting
(randomly fed status), SRC-1 controls the gene
expression of PEPCK and FBP1. Upon a long-
term fasting, after its own accumulation in the liver,
SRC-1 functions to modulate the expression of
C/EBPa through a feed-forward loop in which
SRC-1 uses C/EBPa to transactivate PC. These
sequential molecular events explain how SRC-1
could coordinate hepatic glucose production in
fed and in fasting conditions.
See also Figure S6.
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Role of SRC-1 in Hepatic GluconeogenesisC/EBPa (Figure S5D), while still contributing to the impairment of
glucose output observed in SRC-1-null hepatocytes.
Finally, to further substantiate the importance of the C/EBPa-
PC axis in the control of hepatic gluconeogenesis by SRC-1, we
recently were able to obtain a newly generated mouse model in
which the SRC-1 coactivator was deleted specifically in the liver
(SRC-1 LiKO). As a strong confirmation of our conclusions, these
SRC-1 liver-specific KO mice, fasted for 24 hr, revealed signifi-
cant hypoglycemia compared to the WT (Figure 6H); they also
presented with a clear decrease in expression of the C/EBPa
and PC genes (Figure 6I). Taken together, the totality of our
data confirm the central role that the C/EBPa-PC axis plays in
the control of glucose production by SRC-1 in the liver.
Gene Expression of SRC-1 Correlates with
the Expression Levels of C/EBPa and PC during
the Fed-to-Fasting Transition In Vivo
To further characterize the importance of SRC-1 on the hepatic
glucose production during the fed-to-fasting condition in vivo,
we investigated its kinetic of induction during key metabolic
checkpoints, which are refed, short-fasting (4 hr), and long-fast-
ing (24 hr) animals. Importantly, we found that SRC-1 gene
expression is significantly activated after a short period of fasting
(4 hr) and remained upregulated during 24 hr (Figure 7A). This
result, which suggests an early role of this coactivator on the614 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc.gluconeogenic pathway upon fasting,
correlates well with our observation
showing cAMP as a major fasting signal
activating SRC-1 gene expression in
primary hepatocytes with only a coopera-
tive effect for glucocorticoids (Figure 4E).Moreover, by testing the gene expression of C/EBPa and PC in
those same conditions, we found that C/EBPa was mainly acti-
vated during early fasting (4 hr), whereas PC reached its highest
expression level only in late fasting (24 hr) (Figure 7A). These
observations combined with the totality of our data validated
our proposed model.
Finally, to analyze whether SRC-1may have an impact in path-
ological situations, we checked the level of SRC-1 gene expres-
sion in db/db and ob/ob mice, two commonly studied animal
models for insulin resistance and type 2 diabetes. These mice
are strongly hyperglycemic compared to the WT during fasting
(Figure S6A). Interestingly, we observed a significant reduction
of the SRC-1 gene expression in these prediabetic models (Fig-
ure S6B). These results suggest a key role of SRC-1 as an original
sensor of glucose homeostasis since the gene expression of this
coactivator is increased in fasting when the glucose and the
insulin levels drop and is decreased in situations where produc-
tion of glucose and insulin is ‘‘abnormally’’ high. To validate this
hypothesis, we checked whether the glucose and the insulin
could together modulate the gene expression of SRC-1. Accord-
ingly, we found that a high level of insulin combined with a high
level of glucose significantly repressed the gene expression of
SRC-1 (Figure S6C).
Taken together, our data indicate that SRC-1 acts as a new
coordinator of the gluconeogenic program in vivo. These
Cell Metabolism
Role of SRC-1 in Hepatic Gluconeogenesisfunctions are summarized in the model in Figure 7B. SRC-1
controls key rate-limiting genes involved in the gluconeogenic
program, such as PEPCK, FBP1, and PC. At the molecular level,
the SRC-1 gene is activated by fasting signals (glucagon and
glucocorticoids). The main role of SRC-1 then is to modulate
the expression and the activity of C/EBPa through a feed-forward
loop in which the coactivator SRC-1 uses C/EBPa as the tran-
scription factor to transactivatePC, the rate-limiting gene for initi-
ation of the gluconeogenic program. These sequential molecular
events explain how PC is induced upon fasting in the liver and
also introduce a new role for C/EBPa as an important transcrip-
tion factor for initiation of expression of the PC gene.
DISCUSSION
The transcriptional coactivator SRC-1 was the first cloned
nuclear receptor coactivator (On˜ate et al., 1995), but its physio-
logic roles in vivo remained unclear until recently (O’Malley et al.,
2008). Our interest in this coregulator as a potential coordinator
of metabolic processes emerged from a series of recent obser-
vations. SRC-1 appears to be an important player in global
energy expenditure, as SRC-1 KO animals fed on a high-fat
diet are prone to develop obesity as a result of a net decrease
in adaptive thermogenesis (Picard et al., 2002). Gene expression
microarray analysis of liver target genes of SRC-1 revealed that
this coactivator could control as many as 2% of the genes ex-
pressed in this tissue, placing SRC-1 as an important putative
regulator of common hepatic functions (Jeong et al., 2006). A
report of a genome-wide scan for genes with very strong positive
selection during evolution of populations revealed that the
SRC-1 locus presented the highest rate of genetic variation
and selection in the ancestral African population (Voight et al.,
2006). The fact that evolution mandated retention of a greater
number of genetic modifications in the SRC-1 gene suggests
that a major biological activity of this gene could be to mediate
adaptations to environmental changes in nutrient supplies during
population migrations. In support of this hypothesis, this same
study found evidence for a positive genetic selection in the leptin
receptor (Voight et al., 2006).
To unmask the in vivo impact of the SRC-1 coactivator in the
fed-to-fasting transition, we used KO mice and analyzed the
consequences of SRC-1 deletion on the expression of keymeta-
bolic regulatory genes. Our data suggested a primary role for
SRC-1 in the regulation of the hepatic glucose production. We
were able to exclude an active role for SRC-1 in the control of
several pathways involved in the fed-to-fasting adaptation,
such as glycogenolysis, lipolysis, and glycolysis. This result is
of particular interest when juxtaposed with our recent parallel
study showing that SRC-2 is a crucial modulator of the glycogen-
olysis pathway; SRC-2 KO animals mimic many of the clinical
features of the human glycogen storage disease (type 1a) called
VonGierke’s disease (Chopra et al., 2008). Taken together, these
observations provide strong evidence highlighting the impor-
tance of this family of coregulators as crucial integrators of meta-
bolic pathways and underline the selective and nonredundant
modes of action of the p160 family members in the control of
specific metabolic programs.
Our present study revealed that oneof themajor roles of SRC-1
during fasting is to control the gene expression and the activity ofCell MC/EBPa. This transcription factor is known to be a key player in
the hepatic glucose production as its genetic invalidation in
mice resulted in a lethal hypoglycemia occurring a fewhours after
birth (Wang et al., 1995). Nevertheless, the exact mechanisms
underlying the action of C/EBPa on the gluconeogenic pathway
remained unclear. Indeed, in C/EBPa KO mice, G6Pase and
PEPCK mRNA levels were found to be low just after birth and
then increased to normal and remained high until death (Wang
et al., 1995). The fact that blood glucose concentrations were
dropping despite normal expression levels of PEPCK and
G6Pase strongly suggested that C/EBPa is able to control other
key players of the liver glucose production. Based on our finding,
PC is likely one of these critical missing regulators of gluconeo-
genesis. Indeed, we suggest that C/EBPa via SRC-1 influences
the gene expression of PC, which acts as (1) a critical first step
in the gluconeogenic program by providing oxaloacetate for
subsequent conversion into phosphoenolpyruvate by PEPCK
and (2) a carrier of reducing equivalents (NADH) from mitochon-
dria to thecytoplasm. It is noteworthy that a recent study revealed
that gluconeogenic fluxwas still observed despite the abrogation
of 80% of the PEPCK activity, suggesting that PEPCK could not
be considered anymore as the primary control point of gluconeo-
genesis (Burgess et al., 2007). Clearly, this unexpected observa-
tion shed light on the potential role of other rate-limiting enzymes
of glucose production such as PC, as suggested by the authors
(Burgess et al., 2007). In fact, the concept that PC could have
greater control strength than ‘‘traditional’’ rate-limiting enzyme
such as PEPCK and G6Pase has been previously suggested
(Groen et al., 1986). However, one of the main conclusions of
this study is that the metabolic flux is under the control of the
entire metabolic network rather than each individual enzyme.
Consequently, modifications in the expression or activity of indi-
vidual enzyme do not predictably impact flux through the intact
pathway. Clearly, a coregulator such as SRC-1 which acts as
a ‘‘master regulator’’ by controlling the expression of multiple
enzymes of the same pathway is a strong candidate to fulfill
this complex coordination of metabolic flux. Interestingly, impor-
tant target genes of SRC-1, such as PC, FBP1, and C/EBPa, are
not under the control of PGC-1a, suggesting that SRC-1 employs
uniquemechanisms to coordinate this set of genes in the liver and
reinforcing the hypothesis that themechanismof action of SRC-1
is distinct from that of PGC-1a.
Because of the clear defect observed in glucose production in
SRC-1 KO mice, metabolic compensations were expected to
occur in order to counterbalance this impairment as it has
been reported in numerous other studies done in vivo (Lin
et al., 2004; Rhee et al., 2003). Effectively, a net compensatory
increase in b-oxidation flux (Figures S2D and S2E) and
a decrease in glucose oxidation were seen in our mouse models
(Figure S2F). The fact that b-oxidation is known to play an impor-
tant role in gluconeogenesis by providing NADH and ATP as
energy sources, as well as acetyl-CoA, which serves as an allo-
steric activator of PC enzyme activity (Newgard, 2004), support
our conclusion. The decrease in glycolytic flux and glucose
oxidation in SRC-1/ mice is suggests that these animals are
striving to prevent lethal hypoglycemia during fasting.
In conclusion, we propose an original mode of action of SRC-1
as a central transcriptional player orchestrating the gluconeo-
genic program with only a few overlapping roles with the alreadyetabolism 12, 606–618, December 1, 2010 ª2010 Elsevier Inc. 615
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Role of SRC-1 in Hepatic Gluconeogenesisknown and important regulatory molecules in this pathway—
PGC-1a, CRTC2, and SIRT-1. Clarification of the specific role
for SRC-1 presents a more complete picture of the important
metabolic coordination that exists among this group of coactiva-
tors and extends the emerging concept that select coregulators
indeed are ‘‘master genes’’ with pleiotropic effects on several
crucial physiologic programs. Importantly, a greater under-
standing of gluconeogenesis enhances our effort toward new
therapeutic avenues for metabolic diseases such as type 2
diabetes.
EXPERIMENTAL PROCEDURES
Mice
SRC-1 mice were maintained on a pure C57BL/6J background. SRC-3
knockout mice were maintained on a mixed background (C57BL/6J and
SV129). SRC-1 F/F mice (Yamada et al., 2004) were crossed with Albumin-
Cre (Postic and Magnuson, 2000) mice to generate liver-specific SRC-1
knockout mice (SRC-1 LiKO). We used 8- to 16-week-old male mice and
sex-matched WTs for all in vivo studies. For the liver-selective SRC-1 re-
expression, 16-week-old male mice were exposed to adenoviral mediated
transgenesis (1011 virus particles per mouse), via tail-vein injections as previ-
ously described (Chopra et al., 2008). Mice were sacrificed 4 days after viral
infusion, and blood glucose and MS experiments were performed on fasted
mice (16 hr). For the liver selective C/EBPa re-expression, 8-week-old male
mice were exposed to adenoviral mediated transgenesis (0.5 3 1010 virus
particles per mouse) and sacrificed 7 days after viral infusion, and blood
glucose were performed on fasted (24 hr) mice. High-protein diet (Harlan TD
90018) was provided to the mice during 3 weeks. The 8 weeks db/db and
ob/ob mice and WT littermates were purchased from Harlan. The Baylor
College of Medicine Institutional Animal Care and Utilization Committee
approved all experiments.
Metabolic Studies
We measured blood glucose using a hand-held glucometer (One Touch Ultra,
Lifescan). Insulin levels were measured by ELISA (Mercodia), triglyceride by
colorimetric assays (Roche), and free fatty acids by colorimetric assays
(Wako Pure Chemicals). Hepatic glycogen measurements have been
described previously (Chopra et al., 2008). Glucose tolerance test (GTT), insulin
tolerance test (ITT), and indirect calorimetry were performed as described
(Coste et al., 2008). Glucagon, corticosteroids, IGF-1, and GH were measured
at the Hormone Assay and Analytical Services Core at the Vanderbilt University
(http://hormone.mc.vanderbilt.edu/). Glucose production with a tritiated
glucose (Glucose, D-[3-3H]), lypolysis and physical activity were measured at
the BCM Diabetes and Endocrinology Research Center (DERC) by the Mouse
Metabolism Core (http://www.bcm.edu/diabetescenter/?PMID=9028) as
described in (Chopra et al., 2008; Martinez-Botas et al., 2000). In vivo glucose
production was performed as follows: A micro catheter was inserted into the
jugular vein by survival surgery, and we waited for 4–5 days for complete
recovery. The study was then realized in conscious mice. Overnight-fasted
conscious mice (16 hr) received a priming dose of HPLC-purified [3-3H]
glucose (10 mCi) and then a constant infusion (0.1 mCi/min) of label glucose
for 90 min. Blood samples were collected from the tail vein at 0, 50, 60, 75,
and 90 min to measure the basal glucose production rate. Steady states
were reached within 1 hr of infusion.
Metabolites Profiling Studies
Acylcarnitines and amino acids were analyzed in plasma of fed and fasted
mice. The same metabolites and a panel of organic acids were also measured
in liver extracts of fed and fasted mice. Methods of tissue handling and extrac-
tion have been described previously (Ferrara et al., 2008; Ronnebaum et al.,
2006). Acylcarnitines and amino acids were analyzed by tandem mass spec-
trometry (MS/MS) as described (An et al., 2004; Ferrara et al., 2008; Newgard
et al., 2009; Ronnebaum et al., 2006). All MS analyses employed stable isotope
dilution with internal standards from Isotec (St. Louis, MO), Cambridge Isotope
Laboratories (Andover, MA), and CDN Isotopes (Pointe-Claire, Quebec, CN).616 Cell Metabolism 12, 606–618, December 1, 2010 ª2010 ElsevierA list of all internal standards utilized in these studies has been published (Fer-
rara et al., 2008; Newgard et al., 2009).Flux Measurements
After isolation, hepatocytes were incubated for 24 hr in DMEM containing
5.5 mM glucose (Invitrogen), 1 3 BSA/oleate-palmitate mixture (1% BSA,
0.5 mM oleate-palmitate [oleate:palmitate 2:1]), 10 nM Dexamethsone, and
1mM carnitine. Prior to the fuel oxidation assays, the cells were changed to
a balanced oxidation medium containing 1 mM carnitine and 12.5 mMHEPES,
and 1–3 mCi/ml 14C-labeled tracer. U-[14C]glucose, and 1-[14C]oleate were
purchased from Amersham. Two hundred microliters of 1N NaOH was added
into a center well that was carefully set into the culture well. The culture plate
was then sealed with amicroplate adhesive film and incubated at 37C for 3 hr.
One hundred to two hundred microliters of 70% perchloric acid was injected
into the culture well, and the plate was sealed with another layer of the micro-
plate adhesive film and incubated at room temperature on a shaker for 1 hr at
50 rpm. The NaOH in the center well was then taken into a scintillation vial and
mixed with scintillation fluid for the analysis of 14C. The remaining acid-soluble
metabolites (ASMs) were collected into an eppendorf tube and kept at room
temperature overnight. After centrifugation at 10,000 g for 5 min, approxi-
mately 200 ml of supernatant were used for scintillation counting. A parallel
set of hepatocytes was analyzed for total protein content and used for
normalization.RNA Analysis
Weused standard RNA extraction procedures (RNeasyMini Kit fromQIAGEN).
Reverse transcription was carried out with the Superscript III kit (Invitrogen).
For gene expression analysis, qPCR was performed with sequence-specific
primers and probes from Roche (Universal Probe Library). GAPDH was used
as an internal control for all gene-expression assays. All qPCR primers are
available upon request.Chromatin Immunoprecipitation
In vivo ChIP was performed with liver tissue from mice placed at different key
metabolic status (refed, postabsorptive [fed], and fasting [24 hr]). Formalde-
hyde (1%) was added to produce cross linking during 10 min at room temper-
ature. The rest of the ChIP procedure was performed with the EZ ChIP kit
(Millipore) according to the manufacturer’s protocol. SRC-1 antibody is from
Milipore and C/EBPa antibody is from SantaCruz. qPCR for ChIP was per-
formed with the Sybr-Green technology (Applied Biosystems) with
sequence-specific primers. Results were normalized to input in each case.
Primer sequences are available upon request.Cell Culture, Overexpression, and Transient Transfection
Experiments
Primary mouse hepatocytes were isolated from 8- to 12-week-old mice as
described previously (Chopra et al., 2008). Cells were incubated overnight in
Williams E media (Invitrogen) containing 10% FBS and dexamethasone
108 M before each experiment for attachment. For adenoviral transduction
experiments, SRC-1, PGC-1a, and C/EBPa adenoviruses were used as
described (Lerin et al., 2006; Martı´nez-Jime´nez et al., 2006; Wang et al.,
2004). RNA and protein isolation or glucose production assays were carried
out 48 hr after treatment. For transfection experiments, HeLa cells were trans-
fected with several reporter-gene plasmids containing either the native
C/EBPa promoter (Wang et al., 2004), or a construction with specific mutants
of C/EBP-RE sequences within the C/EBPa promoter realized with a site-
directed mutagenesis kit (Agilent Technologies), or the 600/+300 bp PC
proximal promoter cloned in the pGL-3 plasmid after PCR amplification from
liver genomic DNA (Biochain). We also used pSG5-SRC-1-Flag and different
mutants of SRC-1: DHAT (deletion of the histone acetylase domain), DAD2
(deletion of the activating domain 2), and DAD2+NR (deletion of the activating
domain 2+ the nuclear receptor domain). These constructs were cotransfected
as indicated in each experiment by different expression vectors encoding
SRC-1 in PCR3.1 vector (Invitrogen) as well as C/EBPa, which have been
already described in (Louet et al., 2006). Reporter-gene levels were deter-
mined 48 hr after transfection with Promega reagent.Inc.
Cell Metabolism
Role of SRC-1 in Hepatic GluconeogenesisCoimmunoprecipitation Assays and Western Blot
For coimmunoprecipitation, 293/T cells were transiently transfected with Flag-
SRC-1 and pSV-SPORT1-C/EBPa. Then, HeLa cell lysates were incubated
with anti-Flag (Invitrogen) antibody. The immune complexes were eluted and
subjected to SDS-PAGE. The immunoblot detection was done with anti-
C/EBPa antibody (Santa Cruz). For western blot, we used the SRC-1 antibody
fromSanta Cruz. Coimmunoprecipitation in the liver was performedwith tissue
from fasting (16 hr) SRC-1 WT mice.
In Vitro Glucose Production Assay
Primary hepatocytes were cultured in Williams E media (Invitrogen) supple-
mented with 10% FBS and measured glucose production in glucose and
phenol red-free DMEM (pH 7.4) supplemented with sodium lactate and pyru-
vate with a colorimetric assay (Biovision).
Statistical Analysis
All results are presented as mean + standard error of the mean (SEM). p value
was calculated by unpaired Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and can be found with this
article online at doi:10.1016/j.cmet.2010.11.009.
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